{
    "clinical_study": {
        "@rank": "111114", 
        "arm_group": [
            {
                "arm_group_label": "Propofol", 
                "arm_group_type": "Experimental", 
                "description": "Target controlled infusion propofol, the effect compartment concentration is 3-4\u03bcg/ ml for induction and maintenance of anesthesia."
            }, 
            {
                "arm_group_label": "Etomidate", 
                "arm_group_type": "Experimental", 
                "description": "Target controlled infusion etomidate, the effect compartment concentration is 0.5-1.0\u03bcg/ ml for induction and maintenance of anesthesia."
            }
        ], 
        "brief_summary": {
            "textblock": "Compare the efficacy and safety of closed-loop target controlled infusion of propofol or\n      etomidate at general anesthesia in geriatric patients"
        }, 
        "brief_title": "THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adrenal Suppression", 
            "Hemodynamic Instability"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent.\n\n          2. Scheduled for Endotracheal intubated  and general anesthesia for general\n             surgery patients.\n\n          3. Age 60-75 yrs.\n\n          4. American Society of Anesthesia (ASA) classification I-II.\n\n          5. Expected time of surgery is less than 3 hours.  -\n\n        Exclusion Criteria:\n\n          1. Body mass index is more than 36kg/m2.\n\n          2. Systolic blood pressure\u2265180 mm Hg or <90 mm Hg\uff0cdiastolic blood pressure\u2265110 mm Hg or\n             < 60 mm Hg.\n\n          3. Serious cardiac,cerebral,liver,kidney,lung, endocrine disease or sepsis.\n\n          4. Long term used hormone or adrenal suppression.\n\n          5. Allergy to trial drug or other contraindication.\n\n          6. Difficult airway occurred before,or difficult airway possibly occurred and difficult\n             to extubation.\n\n          7. Abuse of narcotic analgesia or suspected.\n\n          8. Neuromuscular diseases.\n\n          9. Mentally unstable or has a mental illness.\n\n         10. Malignant Hyperthermia.\n\n         11. Pregnant or breast-feeding women.\n\n         12. Attended other trial past 30 days.  -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111265", 
            "org_study_id": "SAHXJTUA01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Propofol", 
                    "Etomidate"
                ], 
                "description": "Remifentanil 0.1-0.2\u03bcg/ ( kg\u2022min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.\nRemifentanil is stopped before skin closure", 
                "intervention_name": "Remifentanil", 
                "intervention_type": "Drug", 
                "other_name": "Ruijie"
            }, 
            {
                "arm_group_label": [
                    "Propofol", 
                    "Etomidate"
                ], 
                "description": "Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.\nCisatracurium is stopped before skin closure.", 
                "intervention_name": "Cisatracurium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Propofol", 
                    "Etomidate"
                ], 
                "description": "Before skin closure, remifentanil is stopped and sufentanyl 0.1\u03bcg/kg is given by intravenous injection.", 
                "intervention_name": "Sufentanil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Propofol", 
                    "Etomidate"
                ], 
                "description": "BiS is maintained at 40-60 during anesthesia.", 
                "intervention_name": "Bispectral index(BIS) monitor", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Etomidate", 
                "Propofol", 
                "Remifentanil", 
                "Sufentanil", 
                "Cisatracurium"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 10, 2014", 
        "number_of_arms": "2", 
        "official_title": "The Comparison of Efficacy and Safety of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients \u2014\u2014A Randomized Controlled Trial.", 
        "overall_official": {
            "affiliation": "Department of Anesthesia, Second Affiliated Hospital of Xi'an Jiaotong University", 
            "last_name": "He Jiaxuan", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The effect compartment concentration of etomidate or propofol are recorded at three time points,including time that patient's loss of eyelash reflex,after 30 minutes of loss of eyelash reflex and when the patient is awake \uff08call then open their eyes).", 
            "measure": "Effect Compartment Concentration", 
            "safety_issue": "No", 
            "time_frame": "From the beginning of induction to paitens'left of PACU, up to 4 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Systolic blood pressure, diastolic blood pressure, heart rate, respiration rate, pulse oxygen saturation recorded every 5 minutes during the operation.", 
                "measure": "vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "From the beginning of induction to skin closure, up to 3 hours"
            }, 
            {
                "description": "The amount of narcotics, sedation and muscle relaxation used in general anesthesia arr recorded when the operation is finished.", 
                "measure": "The amount of drugs", 
                "safety_issue": "No", 
                "time_frame": "From the beginning of induction to skin closure, up to 3 hours"
            }, 
            {
                "description": "3 ml blood sample is collected at 5 time points including before induction,30 minutes,2 hours,24 hours, 48 hours after induction;\nto examine the concentration of Cortisol, Aldosterone and ACTH in serum:", 
                "measure": "Adrenal function", 
                "safety_issue": "Yes", 
                "time_frame": "From entering the operating room to 48 h after induction of anesthesia."
            }
        ], 
        "source": "Second Affiliated Hospital of Xi'an Jiaotong University", 
        "sponsors": {
            "collaborator": {
                "agency": "Chinese Medical Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Second Affiliated Hospital of Xi'an Jiaotong University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}